Response to letter to the editor “Comment on: Clinical safety of ultra-high-dose methylcobalamin in patients with amyotrophic lateral sclerosis: Open-label extension of a phase 2/3 randomized controlled study”

Journal of the Neurological Sciences 2026

View at publisher

Authors: Ryuji Kaji, Takayuki Ishida, Yuishin Izumi

DOI: 10.1016/j.jns.2026.125792

Cited by: 0

References: 5

Fields of Study & Subjects

Amyotrophic Lateral Sclerosis Research Botulinum Toxin and Related Neurological Disorders Peripheral Neuropathies and Disorders

References 5